Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU7-56P is a pseudogene that is related to the U7 small nuclear RNA (U7 snRNA), which is a component of the U7 small nuclear ribonucleoprotein complex involved in histone pre-mRNA processing[1][4]. The RNU7-56P locus itself does not encode a functional RNA; it represents a non-functional copy within the genome[1]. RNU7-56P is classified as a pseudogene, representing a non-functional genomic locus related to the gene encoding U7 small nuclear RNA (U7 snRNA)[1]. The U7 snRNA is a small RNA molecule essential for the 3′ end processing of replication-dependent histone pre-mRNAs[4][5]. The U7 snRNA is a component of the U7 small nuclear ribonucleoprotein (U7 snRNP), which binds the histone downstream element (HDE) in pre-mRNAs to recruit the histone cleavage complex required for correct histone mRNA maturation[4][5]. While functional U7 snRNA plays a crucial role in cell cycle regulation by enabling proper histone biosynthesis~[3][4][5], RNU7-56P does not encode a functional product and has no known impact on biology or disease[1]. The functional molecule, U7 snRNA, is involved in histone RNA processing and has emerging utility in gene therapy platforms; however, RNU7-56P is a pseudogene, not a biologically active target[1][4][5]. The RNU7-56P locus does not represent a therapeutic, druggable, or biomarker target, nor is it implicated in pathology. There is an error in targeting this pseudogene for applications related to functional RNA or protein targets in research or therapy. RNU7-56P should not be considered a therapeutic or research target; there is a misassignment if used as such. For biological and therapeutic relevance, refer to the functional U7 small nuclear RNA, not this pseudogene[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U7 small nuclear 56 pseudogene (RNU7-56P).